	US 12,084,681 B2
	Ex vivo antibody production
Paula Maria Wilhelmina Van Helden, Amsterdam Zuidoost (NL); Mark Jeroen Kwakkenbos, Amsterdam Zuidoost (NL); Hergen Spits, Amsterdam Zuidoost (NL); and Tim Beaumont, Amsterdam Zuidoost (NL)
Assigned to KLING BIOTHERAPEUTICS B.V., Amsterdam (NL)
Filed by KLING BIOTHERAPEUTICS B.V., Amsterdam (NL)
Filed on Sep. 19, 2019, as Appl. No. 16/575,518.
Application 16/575,518 is a division of application No. 15/106,991, abandoned, previously published as PCT/NL2014/050908, filed on Dec. 24, 2014.
Claims priority of application No. 13199584 (EP), filed on Dec. 24, 2013.
Prior Publication US 2020/0149007 A1, May 14, 2020
Int. Cl. C12N 5/0781 (2010.01); A61K 38/00 (2006.01); C07K 16/00 (2006.01); C07K 16/10 (2006.01); C12N 15/06 (2006.01); C12N 15/86 (2006.01); C12P 21/00 (2006.01)

CPC C12N 5/0635 (2013.01) [C07K 16/00 (2013.01); C07K 16/1018 (2013.01); C12N 15/86 (2013.01); C12P 21/005 (2013.01); C07K 2317/14 (2013.01); C12N 2510/00 (2013.01); C12N 2510/02 (2013.01); C12N 2510/04 (2013.01); C12N 2740/13045 (2013.01); C12N 2810/6054 (2013.01)]

19 Claims

1. A method for obtaining antibodies comprising:

inducing, enhancing and/or maintaining expression of Bcl-6, or a rabbit homologue thereof, in a rabbit B cell;

inducing, enhancing and/or maintaining expression of at least one anti-apoptotic nucleic acid molecule in said B cell,

culturing said B cell ex vivo to produce antibodies in a culture medium; and

harvesting antibodies from the culture medium in an amount of at least 100 ng/ml culture medium within 10-14 days from the start of the culturing.